Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Psoriasis Vulgaris AND Plaque Psoriasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    120 result(s) found for: Psoriasis Vulgaris AND Plaque Psoriasis. Displaying page 4 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2015-000839-33 Sponsor Protocol Number: LP0053-1108 Start Date*: 2016-03-23
    Sponsor Name:LEO Pharma A/S
    Full Title: Safety and Effect of LEO 90100 aerosol foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) with Plaque Psoriasis A phase 2 trial evaluating the safety and e...
    Medical condition: Plague Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-005368-10 Sponsor Protocol Number: 1206.5 Start Date*: 2006-07-04
    Sponsor Name:Boehringer Ingelheim GmbH & Co. KG
    Full Title: A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg a...
    Medical condition: Moderate to severe plaque-type psoriasis (defined as involving ≥ 10% body surface area, with minimum disease severity PASI ≥ 10 and with static PGA of at least moderate (score of at least 3)]
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) BE (Completed) ES (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002998-62 Sponsor Protocol Number: ROF-PSOR_104 Start Date*: 2012-12-13
    Sponsor Name:Takeda Pharma A/S
    Full Title: A Randomized, Single-Center, Observer-Blind, Vehicle- and Active Comparator-Controlled Phase 1b Study to Assess the Effect and Local Safety and Tolerability Of Roflumilast and BYK321084 – Phosphod...
    Medical condition: Mild to moderate, chronical, stable Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    15.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002354-38 Sponsor Protocol Number: EMR700515_501 Start Date*: 2008-09-26
    Sponsor Name:Merck Serono Ltd
    Full Title: A Phase IV, prospective, open label multicentre study of Raptiva 1mg/kg/week by subcutaneous injection in adults with moderate to severe chronic plaque psoriasis who have failed previous biologic t...
    Medical condition: Adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to biological therapy with Enbrel
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001697-26 Sponsor Protocol Number: 055-006 Start Date*: 2011-12-12
    Sponsor Name:Professor Reich
    Full Title: Optimising outpatient care in mild to moderate psoriasis by a newly developed ‘Topical Treatment Optimising Programme’ - an international study using Daivobet®/Dovobet® Gel (‘PSO-TOP’)
    Medical condition: Mild to moderate active plaque psoriasis despite topical psoriasis treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) IT (Completed) DE (Completed) GB (Completed) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006487-32 Sponsor Protocol Number: RD.03.SPR. 40041 Start Date*: 2007-02-27
    Sponsor Name:GALDERMA R&D SNC
    Full Title: CLINICAL EFFICACY EVALUATION OF A FIXED COMBINATION OF CALCITRIOL 3 µg/g WITH THREE CONCENTRATIONS (100, 250, 500µg/g) OF CLOBETASOL PROPIONATE AS SPRAY FORMULATION USING THE MODIFIED DUMAS-SCHOLTZ...
    Medical condition: Treatment of psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000518-39 Sponsor Protocol Number: CAIN457A2325 Start Date*: 2018-12-06
    Sponsor Name:Novartis Pharma AG
    Full Title: Multicenter, rAndomized, double-blind, placebo-conTrolled, 52-week stUdy to demonstRatE the efficacy, safety and tolerability of subcutaneous secukinumab injections with 2 mL auto-injectors (300 mg...
    Medical condition: Moderate to severe plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PL (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2020-004081-19 Sponsor Protocol Number: 20-01/BetaSal-S Start Date*: 2021-12-22
    Sponsor Name:Dermapharm AG
    Full Title: Double-blind, randomised clinical study comparing efficacy and safety of Betamethasone dipropionate 0.64 mg/g _ Salicylic acid 30 mg/g Ointment (Test) vs. Diprosalic(R) Ointment (Reference) vs. Veh...
    Medical condition: Chronic stable plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-003972-12 Sponsor Protocol Number: CAEB071A2201 Start Date*: 2005-01-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 2 week multiple ascending dose, double-blind placebo controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of twice daily administration of oral AEB071 and to explore th...
    Medical condition: moderate to severe chronic plaque psoriasis patients
    Disease: Version SOC Term Classification Code Term Level
    M15 10050576 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018355-10 Sponsor Protocol Number: H553000-1001 Start Date*: 2010-06-18
    Sponsor Name:Almirall Hermal GmbH
    Full Title: An Investigator-blind, Controlled Study to Assess the Efficacy of Five Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Two Active Controls in a Psoriasis-P...
    Medical condition: Plaque-type psoriasis (psoriasis vulgaris) for at least 6 months
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022281-27 Sponsor Protocol Number: H553000-1005 Start Date*: 2010-12-20
    Sponsor Name:Almirall Hermal GmbH
    Full Title: An Investigator-blind, Controlled Study to Assess the Efficacy and Safety of different formulations of LAS 41004 Compared to Placebo and to Active Control in a Psoriasis-Plaque-Test
    Medical condition: Plaque-type psoriasis (psoriasis vulgaris) for at least 6 months
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001885-41 Sponsor Protocol Number: DLX105-003-002-001 Start Date*: 2013-07-11
    Sponsor Name:Delenex Therapeutics AG
    Full Title: A multi-center, double-blinded, randomized, placebo-controlled, phase II study to evaluate the safety, tolerability and efficacy of a topical application of DLX105 onto lesional skin in patients wi...
    Medical condition: mild-to-moderate plaque-type psoriasis vulgaris 6 (PASI ≤15)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001632-21 Sponsor Protocol Number: M518101-EU04 Start Date*: 2013-10-01
    Sponsor Name:Maruho Europe Limited
    Full Title: A randomized, double-blind, parallel group phase III multi-center trial to compare twice daily topical application of M518101, Daivonex® and vehicle in patients with plaque psoriasis
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) HU (Completed) PL (Completed) BG (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004640-21 Sponsor Protocol Number: CT327-2003 Start Date*: 2012-02-13
    Sponsor Name:Creabilis Limited
    Full Title: A Randomized, Placebo-controlled Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w topical CT327 when Applied Twice Daily in Subjects with Psoriasis Vulg...
    Medical condition: Psoriasis Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003802-14 Sponsor Protocol Number: CRC-PSO-SKINPEN-A-27 Start Date*: 2016-11-25
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004547-35 Sponsor Protocol Number: IMP27330.1 Start Date*: 2007-01-10
    Sponsor Name:Serono GmbH
    Full Title: Phase IV study to investigate neutrophil downregulation of Thy-1 by Raptiva® (Efalizumab) as a potential responder predictor in patients with moderate to severe plaque psoriasis
    Medical condition: Moderate to severe chronic plaque psoriasis (PASI ≥ 12) failing to respond to, or with a contraindication to, or intolerant to other systemic therapies including cyclosporine, methotrexate and Psor...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001798-41 Sponsor Protocol Number: LP0053-1227 Start Date*: 2015-08-10
    Sponsor Name:LEO Pharma A/S
    Full Title: A psoriasis plaque test trial with LEO 90100 compared to Betesil® in patients with psoriasis vulgaris
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001384-45 Sponsor Protocol Number: H553000-1101 Start Date*: 2011-06-29
    Sponsor Name:Almirall Hermal GmbH
    Full Title: A 22 day bland ointment and reference-controlled, investigator-blind, single center, randomized, proof of concept clinical study with an intraindividual comparison investigating the anti-psoriatic ...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004759-30 Sponsor Protocol Number: LP0113-1123 Start Date*: 2015-03-23
    Sponsor Name:LEO Pharma A/S
    Full Title: A psoriasis plaque test trial with LP0113 spray in patients with psoriasis vulgaris
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000003-20 Sponsor Protocol Number: MEMPSOLAR0001 Start Date*: 2021-06-08
    Sponsor Name:Aarhus University Hospital
    Full Title: AN INVESTIGATOR INITIATED, PHASE 4, OPEN-LABEL, SINGLE-ARM, SINGLE-CENTER STUDY INVESTIGATING THE RESIDUAL DISEASE MEMORY IN PSORIASIS SKIN DURING ENSTILAR® AND NARROW-BAND ULTRAVIOLET B THERAPY. ...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 06:48:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA